Polydeoxyribonucleotide in the Treatment of Tendon Disorders, from Basic Science to Clinical Practice: A Systematic Review
International Journal of Molecular Sciences · 26.02.2023 · 24 (5) · 4582
DOI: 10.3390/ijms24054582 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 26.02.2023. Verfasst von Davide Bizzoca und 7 weiteren Autor:innen. Beteiligte Einrichtung: UOSD Spine Surgery, AOU Consorziale Policlinico, 70124 Bari, Italy. Hauptthemen laut MEDLINE: Tendinopathy, Rotator Cuff Injuries, Achilles Tendon. Die Arbeit wurde bisher 24-mal zitiert (Crossref) und nennt 47 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Polydeoxyribonucleotide (PDRN) is a proprietary and registered drug with several beneficial effects, including tissue repairing, anti-ischemic action, and anti-inflammatory properties. The present study aims to summarize the current evidence about PRDN’s clinical effectiveness in the management of tendon disorders. From January 2015 to November 2022, OVID-MEDLINE®, EMBASE, Cochrane Library, SCOPUS, Web of Science, Google Scholar and PubMed were searched to identify relevant studies. The methodological quality of the studies was evaluated, and relevant data were extracted. Nine studies (two in vivo studies and seven clinical studies) were finally included in this systematic review. Overall, 169 patients (male: 103) were included in the present study. The effectiveness and safeness of PDRN has been investigated in the management of the following diseases: plantar fasciitis; epicondylitis; Achilles tendinopathy; pes anserine bursitis; chronic rotator cuff disease. No adverse effects have been recorded in the included studies and all the patients showed an improvement in clinical symptoms during the follow-up. PDRN are a valid emerging therapeutic drug in the treatment of tendinopathies. Further multicentric randomized clinical studies are needed to better define the therapeutic role of PDRN, especially in combined clinical protocols.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- UOSD Spine Surgery, AOU Consorziale Policlinico, 70124 Bari, Italy.
- PhD. Course in Public Health, Clinical Medicine and Oncology, Department DiMePre-J, University of Bari "Aldo Moro", Piazza Giulio Cesare 11, 70124 Bari, Italy.
- Orthopaedics Unit, Department DiBraiN, School of Medicine, University of Bari "Aldo Moro", AOU Consorziale Policlinico, 70124 Bari, Italy.
- National Centre for Chemicals, Cosmetic Products and Consumer Protection, National Institute of Health, 00161 Rome, Italy.
ORCID-Profile: Davide Bizzoca, Lorenzo Moretti
Zitieren
APA
Bizzoca, D., Brunetti, G., Moretti, L., Piazzolla, A., Vicenti, G., Moretti, F. L., Solarino, G., & Moretti, B. (2023). Polydeoxyribonucleotide in the Treatment of Tendon Disorders, from Basic Science to Clinical Practice: A Systematic Review. International Journal of Molecular Sciences, 24(5), 4582. https://doi.org/10.3390/ijms24054582
Vancouver
Bizzoca D, Brunetti G, Moretti L, Piazzolla A, Vicenti G, Moretti FL, et al. Polydeoxyribonucleotide in the Treatment of Tendon Disorders, from Basic Science to Clinical Practice: A Systematic Review. International Journal of Molecular Sciences. 2023;24(5):4582. doi:10.3390/ijms24054582
BibTeX
@article{Bizzoca2023,
author = {Bizzoca, Davide and Brunetti, Giovanni and Moretti, Lorenzo and Piazzolla, Andrea and Vicenti, Giovanni and Moretti, Francesco Luca and Solarino, Giuseppe and Moretti, Biagio},
title = {Polydeoxyribonucleotide in the Treatment of Tendon Disorders, from Basic Science to Clinical Practice: A Systematic Review},
journal = {International Journal of Molecular Sciences},
year = {2023},
volume = {24},
number = {5},
pages = {4582},
doi = {10.3390/ijms24054582}
}
EUVIMED